Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROCODONE BITARTRATE AND IBUPROFEN vs ACTRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Short-term (up to 10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Mild to moderate pain,Fever
One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
Hydrocodone: 3.8-4.5 hours (immediate release); Ibuprofen: 1.8-2.5 hours (racemic, S-enantiomer slightly shorter). Clinical context: dosing every 4-6 hours due to hydrocodone half-life.
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Hydrocodone is primarily metabolized by CYP3A4 and CYP2D6 enzymes to hydromorphone (active) and norhydrocodone (inactive). Ibuprofen is metabolized by CYP2C9 to inactive metabolites (hydroxyibuprofen and carboxyibuprofen).
Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1, SULT1A3), and oxidation (CYP2E1, CYP3A4) to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Hydrocodone: primarily renal (60-70% as metabolites, <12% unchanged); Ibuprofen: primarily renal (90% as metabolites and conjugates, <1% unchanged), minor biliary/fecal.
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Hydrocodone: ~19% bound to plasma proteins; Ibuprofen: >99% bound to albumin.
>99% bound to albumin.
Hydrocodone: 3.3-4.7 L/kg; Ibuprofen: 0.1-0.2 L/kg. High Vd for hydrocodone indicates extensive tissue distribution; low Vd for ibuprofen indicates plasma and interstitial fluid confinement.
0.1-0.2 L/kg; indicates limited extravascular distribution.
Hydrocodone: mean absolute bioavailability ~70-80% (oral); Ibuprofen: ~80-100% (oral, rapid absorption).
Oral: 70-90% (first-pass metabolism minimal); IV: 100%.
GFR 30-60 m L/min: Use with caution, consider reducing dose or increasing interval. GFR <30 m L/min: Not recommended due to accumulation of ibuprofen and hydrocodone metabolites.
GFR <30 m L/min: Avoid use. GFR 30-50 m L/min: Reduce dose to 50% of normal, maximum 600 mg/day.
Child-Pugh Class B: Start with lowest possible dose, monitor closely. Child-Pugh Class C: Contraindicated due to risk of toxicity.
Child-Pugh Class B: Reduce dose by 50%; maximum 600 mg/day. Child-Pugh Class C: Contraindicated.
Not recommended for use in pediatric patients; safety and efficacy not established.
Children ≥12 years: 400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Children <12 years: Not recommended.
Initiate with lowest effective dose (e.g., half tablet) and monitor for CNS and respiratory depression; reduce maximum daily dose to 4 tablets due to increased sensitivity and renal impairment.
Initiate at 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from ibuprofen (NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation, which can be fatal).
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases involve use of acetaminophen at doses exceeding 4000 mg per day, often involving more than one acetaminophen-containing product.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity; gastrointestinal bleeding, ulceration, and perforation; cardiovascular thrombotic events; hypertension; renal toxicity; anaphylactoid reactions; serious skin reactions; use in pregnancy; use in breastfeeding; use in hepatic impairment; use in renal impairment; use in elderly; use in patients with bleeding disorders.
Hepatotoxicity: risk increased with chronic alcohol use, liver disease, or use of other acetaminophen-containing products. Avoid exceeding 4000 mg/day. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. Hypersensitivity reactions: anaphylaxis.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction; hypersensitivity to hydrocodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain relief in the setting of coronary artery bypass graft (CABG) surgery; use within 14 days of monoamine oxidase inhibitor (MAOI) therapy.
Severe hepatic impairment or active liver disease. Known hypersensitivity to acetaminophen or any component of the formulation.
Grapefruit and grapefruit juice may increase hydrocodone levels and risk of adverse effects; avoid concurrent use. Alcohol potentiates CNS depression and increases GI bleeding risk; avoid altogether. High-fat meals may delay absorption of hydrocodone, but clinical impact is minimal; take consistently with or without food.
Avoid alcohol; may increase risk of GI bleeding. No specific food restrictions, but taking with food can reduce gastrointestinal irritation. Maintain adequate hydration to prevent renal impairment.
Pregnancy Category C: No adequate studies in pregnant women. Ibuprofen (NSAID) is associated with increased risk of premature closure of ductus arteriosus and oligohydramnios in third trimester; avoid after 30 weeks gestation. Hydrocodone may cause respiratory depression in neonate if used near term; chronic use may lead to neonatal opioid withdrawal syndrome. First trimester: limited data, but NSAIDs may increase risk of miscarriage; hydrocodone not associated with major malformations. Second trimester: generally considered safer, but risks remain. Third trimester: avoid NSAIDs; hydrocodone use only if benefit outweighs risk.
First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios with prolonged use. Avoid after 30 weeks gestation.
Limited data; both drugs excreted into breast milk. Ibuprofen M/P ratio ~0.01, considered compatible. Hydrocodone M/P ratio ~2.0; low levels in milk but risk of infant sedation and respiratory depression. Use caution; monitor infant for drowsiness, difficulty breastfeeding. American Academy of Pediatrics considers hydrocodone as 'usually compatible' but avoid when possible. Alternatives preferred.
Excreted in breast milk; M/P ratio 0.15. Low oral bioavailability to infant; considered compatible with breastfeeding. Monitor infant for sedation or feeding problems.
No specific pharmacokinetic studies; however, pregnancy increases clearance and volume of distribution for both drugs. Ibuprofen: dose adjustments not typically recommended, but due to renal effects and fetal risks, use lowest effective dose for shortest duration. Hydrocodone: increased clearance may require higher doses to achieve analgesic effect; consider patient-specific titration. However, due to neonatal risks, minimize use and duration.
Dose adjustment not typically required; however, due to increased renal clearance and volume of distribution in pregnancy, higher doses may be needed to achieve therapeutic effect. Use lowest effective dose for shortest duration.
Hydrocodone/ibuprofen combines an opioid agonist with an NSAID. Be aware of additive risks: respiratory depression, sedation, GI bleeding, renal impairment, and cardiovascular thrombotic events. Avoid in patients with severe asthma, GI obstruction, or after recent bariatric surgery. Use lowest effective dose for shortest duration. Monitor for serotonin syndrome if used with other serotonergic drugs. Abrupt discontinuation after prolonged use may cause withdrawal.
ACTRON (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) for short-term management of moderate to severe acute pain, typically not exceeding 5 days due to risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with active peptic ulcer disease, bleeding diathesis, or advanced renal disease. Monitor renal function and signs of bleeding. Use lowest effective dose for shortest duration. May cause bronchospasm in aspirin-sensitive asthma.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Hydrocodone can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, other opioids) while taking this medication.,Ibuprofen may increase risk of stomach bleeding; report black/tarry stools, coffee-ground vomit, or abdominal pain.,Avoid other NSAIDs (e.g., aspirin, naproxen) or COX-2 inhibitors to prevent additive GI and renal toxicity.,Store securely away from children and others; dispose of unused medication via take-back programs.,Do not abruptly stop after long-term use; withdrawal symptoms may occur (anxiety, sweating, nausea).
Take with food or milk to reduce stomach upset.,Do not take for more than 5 days as prescribed; longer use increases risk of serious side effects.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Report any signs of bleeding (e.g., black stools, vomiting blood), unusual bruising, or decreased urination.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting your doctor.,Inform your doctor about all medications, especially blood thinners (e.g., warfarin) and diuretics.,If you have asthma, be aware of potential bronchospasm; seek immediate help if you have breathing trouble.,Not recommended during pregnancy, especially in the third trimester.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROCODONE BITARTRATE AND IBUPROFEN vs ACTRON, answered by our medical review team.
HYDROCODONE BITARTRATE AND IBUPROFEN is a NSAID that works by Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.. ACTRON is a NSAID that works by Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROCODONE BITARTRATE AND IBUPROFEN and ACTRON depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROCODONE BITARTRATE AND IBUPROFEN is: One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. The standard adult dose of ACTRON is: Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROCODONE BITARTRATE AND IBUPROFEN and ACTRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROCODONE BITARTRATE AND IBUPROFEN is classified as Category D/X. Pregnancy Category C: No adequate studies in pregnant women. Ibuprofen (NSAID) is associated with increased risk of premature closure of ductus arteriosus and oligohydramnios in th. ACTRON is classified as Category C. First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.